News & Events about Moleculin Biotech Inc.
- Live video webcast presentations with participating companies -FRENCHTOWN, NJ / ACCESSWIRE / January 11, 2023 / JTC Team ('JTC'), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2023 Companies to Watch Event...
StockNews.com began coverage on shares of Moleculin Biotech (NASDAQ:MBRX Get Rating) in a research report released on Thursday morning. The brokerage issued a sell rating on the stock. Separately, Oppenheimer dropped their price target on shares of Moleculin Biotech from $14.00 to $5.00 in a...
Moleculin Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML) Moleculin Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C...
Moleculin Granted FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme Moleculin Granted FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme PR Newswire HOUSTON, Dec. 7, 2022 HOUSTON, Dec. 7, 2022 /PRNewswire/ -- Moleculin Biotech, Inc...
Ticker Report
2 months ago
StockNews.com started coverage on shares of Moleculin Biotech (NASDAQ:MBRX Get Rating) in a research report sent to investors on Sunday morning. The brokerage issued a sell rating on the stock. A number of other research firms also recently weighed in on MBRX. Oppenheimer decreased their ...